MA46085A - Dérivés d'imidazole et leur utilisation dans le traitement de maladies ou de cancers auto-immuns ou inflammatoires - Google Patents
Dérivés d'imidazole et leur utilisation dans le traitement de maladies ou de cancers auto-immuns ou inflammatoiresInfo
- Publication number
- MA46085A MA46085A MA046085A MA46085A MA46085A MA 46085 A MA46085 A MA 46085A MA 046085 A MA046085 A MA 046085A MA 46085 A MA46085 A MA 46085A MA 46085 A MA46085 A MA 46085A
- Authority
- MA
- Morocco
- Prior art keywords
- autoimmune
- cancers
- treatment
- inflammatory diseases
- imidazole derivatives
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000001363 autoimmune Effects 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614934.6A GB201614934D0 (en) | 2016-09-02 | 2016-09-02 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46085A true MA46085A (fr) | 2019-07-10 |
Family
ID=57140084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046085A MA46085A (fr) | 2016-09-02 | 2017-08-31 | Dérivés d'imidazole et leur utilisation dans le traitement de maladies ou de cancers auto-immuns ou inflammatoires |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20190175571A1 (fr) |
| EP (1) | EP3507283A1 (fr) |
| JP (1) | JP2019526577A (fr) |
| KR (1) | KR20190042701A (fr) |
| CN (1) | CN109790147A (fr) |
| AR (1) | AR109487A1 (fr) |
| AU (1) | AU2017317724A1 (fr) |
| BR (1) | BR112019004241A2 (fr) |
| CA (1) | CA3035312A1 (fr) |
| CL (1) | CL2019000538A1 (fr) |
| CO (1) | CO2019001871A2 (fr) |
| CR (1) | CR20190106A (fr) |
| DO (1) | DOP2019000047A (fr) |
| EA (1) | EA201990410A1 (fr) |
| GB (1) | GB201614934D0 (fr) |
| JO (1) | JOP20190029A1 (fr) |
| MA (1) | MA46085A (fr) |
| MX (1) | MX2019002491A (fr) |
| PE (1) | PE20190478A1 (fr) |
| PH (1) | PH12019500460A1 (fr) |
| SG (1) | SG11201901673SA (fr) |
| TW (1) | TW201817724A (fr) |
| UY (1) | UY37393A (fr) |
| WO (1) | WO2018041947A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY199759A (en) | 2016-09-02 | 2023-11-21 | Tisento Therapeutics Inc | Fused bicyclic sgc stimulators |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| CN111588721B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物zl0580用于制备预防或治疗非洲猪瘟药物的新用途 |
| CN111686114B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物i-bet-762用于制备预防或治疗非洲猪瘟药物的新用途 |
| CN111686107B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物plx51107用于制备预防或治疗非洲猪瘟药物的新用途 |
| CN111588725B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物arv-825用于制备预防或治疗非洲猪瘟药物的新用途 |
| EP4558224A1 (fr) * | 2022-07-21 | 2025-05-28 | Tay Therapeutics Limited | Pyrroles et imidazoles utilisés comme inhibiteurs de protéines bet |
| CN117257964B (zh) * | 2023-10-25 | 2024-04-02 | 苏州大学 | 基于碳酸氢铵的微波诱导吲哚美辛原位无定形化增溶技术 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3406329A1 (de) * | 1984-02-22 | 1985-08-22 | Merck Patent Gmbh, 6100 Darmstadt | Pyridone |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| DE4034060A1 (de) * | 1990-10-26 | 1992-04-30 | Basf Ag | Biskationische azofarbstoffe |
| DE19809994B4 (de) * | 1997-03-19 | 2006-02-09 | Basf Ag | Clathrate von Bis-[6-hydroxy-4-methyl-5-(3-methylimidazolium-1-yl)-3-(phen-4-ylazo)-pyridin-2-on]ethylen |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
| JP4388997B2 (ja) * | 2006-09-05 | 2009-12-24 | 協和発酵キリン株式会社 | イミダゾール誘導体 |
| EA201001456A1 (ru) * | 2008-03-21 | 2011-06-30 | Новартис Аг | Новые гетероциклические соединения и их применение |
| JP5627574B2 (ja) * | 2008-06-03 | 2014-11-19 | インターミューン， インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| KR20130044381A (ko) * | 2010-03-04 | 2013-05-02 | 머크 샤프 앤드 돔 코포레이션 | 카테콜 ｏ－메틸 트랜스퍼라제의 억제제 및 정신병적 장애의 치료에서의 그의 용도 |
| AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014096965A2 (fr) * | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Nouveaux composés hétérocycliques en tant qu'inhibiteurs de bromodomaine |
| CN104788423B (zh) * | 2015-03-13 | 2016-10-26 | 成都理工大学 | 一种新的囊性纤维化跨膜传导调节因子抑制剂 |
| GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
-
2016
- 2016-09-02 GB GBGB1614934.6A patent/GB201614934D0/en not_active Ceased
-
2017
- 2017-06-16 JO JOP/2019/0029A patent/JOP20190029A1/ar unknown
- 2017-08-31 AU AU2017317724A patent/AU2017317724A1/en not_active Abandoned
- 2017-08-31 US US16/326,991 patent/US20190175571A1/en not_active Abandoned
- 2017-08-31 MX MX2019002491A patent/MX2019002491A/es unknown
- 2017-08-31 EA EA201990410A patent/EA201990410A1/ru unknown
- 2017-08-31 BR BR112019004241A patent/BR112019004241A2/pt not_active Application Discontinuation
- 2017-08-31 CN CN201780059730.0A patent/CN109790147A/zh active Pending
- 2017-08-31 CA CA3035312A patent/CA3035312A1/fr not_active Abandoned
- 2017-08-31 EP EP17758878.7A patent/EP3507283A1/fr not_active Withdrawn
- 2017-08-31 UY UY0001037393A patent/UY37393A/es not_active Application Discontinuation
- 2017-08-31 JP JP2019511919A patent/JP2019526577A/ja active Pending
- 2017-08-31 AR ARP170102425A patent/AR109487A1/es unknown
- 2017-08-31 MA MA046085A patent/MA46085A/fr unknown
- 2017-08-31 SG SG11201901673SA patent/SG11201901673SA/en unknown
- 2017-08-31 PE PE2019000455A patent/PE20190478A1/es unknown
- 2017-08-31 CR CR20190106A patent/CR20190106A/es unknown
- 2017-08-31 KR KR1020197009266A patent/KR20190042701A/ko not_active Ceased
- 2017-08-31 WO PCT/EP2017/071868 patent/WO2018041947A1/fr not_active Ceased
- 2017-08-31 TW TW106129714A patent/TW201817724A/zh unknown
-
2019
- 2019-02-27 CO CONC2019/0001871A patent/CO2019001871A2/es unknown
- 2019-02-28 DO DO2019000047A patent/DOP2019000047A/es unknown
- 2019-02-28 CL CL2019000538A patent/CL2019000538A1/es unknown
- 2019-03-01 PH PH12019500460A patent/PH12019500460A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3507283A1 (fr) | 2019-07-10 |
| BR112019004241A2 (pt) | 2019-06-04 |
| PH12019500460A1 (en) | 2019-12-16 |
| CL2019000538A1 (es) | 2019-05-17 |
| CO2019001871A2 (es) | 2019-03-08 |
| CR20190106A (es) | 2019-05-02 |
| AR109487A1 (es) | 2018-12-12 |
| US20190175571A1 (en) | 2019-06-13 |
| GB201614934D0 (en) | 2016-10-19 |
| PE20190478A1 (es) | 2019-04-04 |
| DOP2019000047A (es) | 2019-03-15 |
| KR20190042701A (ko) | 2019-04-24 |
| JOP20190029A1 (ar) | 2019-02-25 |
| CN109790147A (zh) | 2019-05-21 |
| AU2017317724A1 (en) | 2019-03-21 |
| TW201817724A (zh) | 2018-05-16 |
| EA201990410A1 (ru) | 2019-09-30 |
| JP2019526577A (ja) | 2019-09-19 |
| UY37393A (es) | 2018-03-23 |
| WO2018041947A1 (fr) | 2018-03-08 |
| CA3035312A1 (fr) | 2018-03-08 |
| SG11201901673SA (en) | 2019-03-28 |
| MX2019002491A (es) | 2019-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46085A (fr) | Dérivés d'imidazole et leur utilisation dans le traitement de maladies ou de cancers auto-immuns ou inflammatoires | |
| MA45550A (fr) | Dérivés de diazépinone et leur utilisation dans le traitement des infections par l'hépatite b | |
| MA50790A (fr) | Posologie de vidofludimus à utiliser dans la prévention ou le traitement de maladies inflammatoires chroniques et/ou auto-immunes | |
| MA52886A (fr) | Composés de purinone et leur utilisation dans le traitement du cancer | |
| EP3858977A4 (fr) | Souche pour la prévention et le traitement de maladies métaboliques et utilisation associée | |
| MA45089A (fr) | Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes | |
| SI3240554T1 (sl) | Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA49458A (fr) | Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques | |
| EP3337465A4 (fr) | Compositions et méthodes d'utilisation en association destinées au traitement et au diagnostic de maladies auto-immunes | |
| EP3661955A4 (fr) | Conjugués de cytokine pour le traitement de maladies auto-immunes | |
| MA45122A (fr) | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer | |
| EP3621973A4 (fr) | Composés pour la prévention et le traitement de maladies et leur utilisation | |
| IL263132B (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| EP3796920A4 (fr) | Compositions d'arnt/pré-miarn et leur utilisation dans le traitement du cancer | |
| SI3774897T1 (sl) | Postopki in sistemi za selekcijo in zdravljenje bolnikov z vnetnimi boleznimi | |
| MA56392A (fr) | Dérivés de 2h-indazole et leur utilisation dans le traitement de maladies | |
| MA49884A (fr) | Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer | |
| MA43767A (fr) | Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer | |
| MA46061A (fr) | Traitement ascaroside de maladies auto-immunes et inflammatoires | |
| EP3440083A4 (fr) | Composés imidazo [1,5-a]pyrimidinyl carboxamide et leur utilisation dans le traitement de troubles médicaux | |
| EP3937980A4 (fr) | Miarn modifiés et leur utilisation dans le traitement du cancer | |
| EP3639833A4 (fr) | Agent pour la prévention ou le traitement de maladies liées à la graisse et/ou de l'inflammation | |
| EP3600304A4 (fr) | Alcaloïdes berbérine dans la prévention et/ou le traitement d'une maladie intestinale | |
| MA47450A (fr) | Sulfinylpyridines et leur utilisation dans le traitement du cancer |